[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiotherapy":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,121,0,25,[9,49,72,99,123,149,168,190,228,253,278,298,324,348,374,397,426,448,480,513,534,558,592,619,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100646505","phase-3-short-course-radiotherapy-followed-by-capox-with-or-without-iparomlimab-and-tuvonralimab-in-pmmrmss-locally-advanced-rectal-cancer-100646505",false,"NCT07686640","Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR\u002FMSS Locally Advanced Rectal Cancer","Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR\u002FMSS Locally Advanced Rectal Cancer (SCRIT): A Multicenter Phase III Randomized Controlled Trial","SCRIT","Inclusion Criteria:\n\n* Patients aged 18-75 years with histologically confirmed pMMR\u002FMSS rectal adenocarcinoma are eligible if they have MRI-defined clinical stage II or III disease according to AJCC 8th edition, tumor located within 12 cm from the anal verge, and at least one high-risk feature, including cT4b, cN2, EMVI positivity, MRF positivity, lateral lymph node positivity, tumor deposits, or tumor located ≤5 cm from the anal verge. Patients must have no distant metastasis, ECOG performance status 0-1, life expectancy greater than 6 months, and adequate hematologic, hepatic, and renal function\n\nExclusion Criteria:\n\n* active or prior autoimmune disease requiring systemic treatment, use of immunosuppressive therapy or systemic corticosteroids at immunosuppressive doses, severe hypersensitivity to monoclonal antibodies, uncontrolled cardiac disease, significant coagulopathy or bleeding tendency, active infection, interstitial lung disease or severe pulmonary dysfunction, HIV infection or active hepatitis, prior or concurrent malignancy except specified cured cancers, recent investigational drug use, planned use of other systemic antitumor therapy during the study, pregnancy or breastfeeding, and any other condition judged by the investigator to make participation unsuitable.","ALL","18 Years","75 Years",{"count":22,"type":23},180,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","This multicenter, randomized, controlled, phase III trial evaluates whether adding iparomlimab and tuvonralimab injection to CAPOX consolidation chemotherapy after short-course radiotherapy improves tumor response in patients with treatment-naive, proficient mismatch repair\u002Fmicrosatellite-stable (pMMR\u002FMSS) locally advanced rectal adenocarcinoma. Eligible patients will be randomly assigned in a 1:1 ratio to receive short-course radiotherapy followed by CAPOX plus iparomlimab and tuvonralimab, or short-course radiotherapy followed by CAPOX alone.\n\nAfter total neoadjuvant therapy, patients with a clinical complete response may undergo a Watch-and-Wait strategy, whereas other patients will undergo total mesorectal excision according to standard clinical practice. The primary endpoint is complete response rate, defined as pathologic complete response after surgery or clinical complete response sustained for more than 1 year. Secondary endpoints include 3-year relapse-free survival, 3-year overall survival, sphincter preservation rate, and grade 3-4 acute adverse events. Exploratory analyses will assess tissue and blood biomarkers associated with treatment response.",[29,30,31],"Local Advanced Rectal Cancer","Radiotherapy","Immunotherapy",[33,34,35],"local advanced rectal cancer","radiotherapy","immunotherapy","RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-18","ACTUAL",{"date":42,"type":40},"2026-08-15",{"date":44,"type":23},"2030-07-15",{"name":46,"class":47},"Shandong Cancer Hospital and Institute","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100575132","phase-2-assessment-of-adebelizumab-combined-with-chemotherapy-in-concurrent-radiotherapy-versus-sequential-radiotherapy-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-100575132","NCT06768307","Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.","Inclusion Criteria:\n\n* Age ≥18 years, no gender restrictions;\n* Confirmed pathological diagnosis of extensive-stage small cell lung cancer (ES-SCLC), defined as disease extending beyond one hemithorax, including malignant pleural and pericardial effusions or hematogenous metastases (according to the Veterans Administration Lung Cancer Study Group, VALG staging); stage IV (any T, any N, M1a\u002Fb\u002Fc) according to the AJCC (8th edition), or T3-4 due to multiple pulmonary nodules or tumor\u002Fnodule size too large to be included in a tolerable radiation therapy plan;\n* Participants have not received systemic treatment for extensive-stage SCLC;\n* No more than 5 lesions (including metastatic foci), with at least one measurable lesion (according to RECIST v1.1);\n* ECOG performance status score of 0-2;\n* Life expectancy ≥3 months;\n* Consented and signed the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures;\n* Normal major organ function, meeting the following criteria (without symptomatic treatment within 14 days): a) Hematology:\n\nHemoglobin (Hb) ≥90g\u002FL; Platelet (PLT) ≥100×10\\^9\u002FL; Neutrophil count (ANC) ≥1.5×10\\^9\u002FL; White blood cell count (WBC) ≥3.0×10\\^9\u002FL;\n\nLymphocyte ≥0.5×10\\^9\u002FL; b) Biochemistry:\n\nAlanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) ≤ 2.5×ULN; For those with liver metastasis, ALT, AST≤5 ULN; For those with liver or bone metastasis: ALP ≤5 ULN; Total serum bilirubin (TBIL) ≤1.5×ULN (for Gilbert's syndrome participants ≤3×ULN); Albumin (ALB) ≥3 g\u002FdL;\n\nRenal function: Serum creatinine ≤1.5 x ULN or creatinine clearance rate (CrCl) ≥50mL\u002Fminute (using Cockcroft\u002FGault formula); c) Coagulation:\n\nActivated partial thromboplastin time (APTT), International Normalized Ratio (INR), Prothrombin Time (PT) ≤1.5×ULN; d) Others: Lipase ≤1.5 x ULN. Participants with lipase \\>1.5 x ULN without clinical or radiological evidence of pancreatitis can be included; e) Doppler echocardiography: Left ventricular ejection fraction (LVEF) ≥50%;\n\n* Female participants of childbearing potential must have a negative serum HCG test within 72 hours before the first dose, not breastfeeding, and must use a medically recognized contraceptive method (such as intrauterine devices, birth control pills, or condoms) during the study treatment and for 2 months after the last dose of Adebrelimab or 6 months after the last dose of Carboplatin\u002FEtoposide (whichever is longer); male participants with partners of childbearing potential must be surgically sterilized or agree to use highly effective contraception during the trial and for 2 months after the last dose of Adebrelimab or 3 months after the last dose of Carboplatin\u002FEtoposide (whichever is longer), and no sperm donation during the study.\n\nExclusion Criteria:\n\n* Participants who have previously received any T-cell co-stimulation or immune checkpoint therapy, including but not limited to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1\u002F2 inhibitors, CD137 agonists, or other T-cell targeted drugs.\n* Participants who have previously received chemoradiotherapy for limited-stage SCLC;\n* Participants with clinically symptomatic central nervous system metastases (such as brain, spinal cord), or leptomeningeal metastases; participants with active or new CNS metastases found on imaging during the screening period are not included. (Asymptomatic untreated CNS metastases with a lesion size \\\u003C1cm are allowed to be included);\n* Participants with multiple liver metastases (isolated liver metastasis participants with metastasis \\\u003C2cm can be included)\n* Participants with spinal cord compression;\n* Participants with active autoimmune diseases requiring systemic treatment (such as disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years before the first dose, or with a history of autoimmune diseases and expected recurrence. Replacement therapies (such as thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment;\n* Diagnosed with immune deficiency or receiving systemic glucocorticoid treatment or any other form of immunosuppressive therapy within 14 days before the first dose; the use of physiological doses of glucocorticoids (≤10 mg\u002Fday of prednisone or equivalent) is allowed;\n* Participants who have had arterial\u002Fvenous thrombotic events within 6 months before the first dose, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism, etc.), deep vein thrombosis, and pulmonary embolism;\n* Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia (such as cryptogenic organizing pneumonia), drug-induced pneumonia, or idiopathic pneumonia, or evidence of active pneumonia on chest computed tomography (CT) at screening (participants with active tuberculosis are not included);\n* Participants who have undergone major surgical treatment or significant traumatic injury within 28 days before the first dose;\n* Participants who have received or plan to receive preventive vaccines or live-attenuated vaccines within 4 weeks before the first dose;\n* Participants who have received other trial medications or participated in another interventional clinical study within 4 weeks before signing the ICF;\n* Participants with other malignancies that require active treatment within 5 years (except for those with a \\>90% 5-year survival rate such as fully treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, localized prostate cancer after radical surgery, localized bladder cancer, ductal carcinoma in situ after radical surgery, or in situ breast cancer);\n* Participants with any severe and\u002For uncontrolled diseases, including: a) Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90mmHg) participants; history of hypertensive crisis or hypertensive encephalopathy; b) Uncontrolled cardiac clinical symptoms or diseases such as ≥grade 2 myocardial ischemia or myocardial infarction, uncontrollable arrhythmias (including men QTc ≥450ms, women QTc ≥470ms), and ≥grade 2 congestive heart failure (New York Heart Association, NYHA classification), unstable angina, myocardial infarction within 24 weeks, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; c) Active or uncontrolled severe infections (≥CTC AE grade 2 infections), including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia, unexplained fever \\>38.5℃ before the first dose. d) Liver cirrhosis, active hepatitis\\*; \\*Active hepatitis - Hepatitis B reference: HBsAg positive, exceeding the upper limit of normal (1000 copies\u002Fml or 500 IU\u002Fml); participants with past Hepatitis B virus (HBV) infection or cured HBV infection (defined as the presence of hepatitis B core antibody \\[HBcAb\\] and absence of HbsAg, and normal HBV DNA values detected during the screening period can be included; \\*Hepatitis C reference: HCV antibody positive, and HCV viral load exceeds the upper limit of normal\u002FHCV RNA or HCV Ab indicates acute or chronic infection; e) HIV positive or known Acquired Immune Deficiency Syndrome (AIDS); f) Urine routine suggests urinary protein ≥++, and confirmed 24-hour urinary protein quantification \\>1.0 g;\n* Participants with clinically symptomatic third-space fluid accumulation, such as pericardial effusion, pleural effusion, and abdominal effusion requiring repeated drainage (such as once a month or more frequently) that cannot be controlled by tapping or other treatments;\n* Participants whose adverse events (except for alopecia) caused by previous treatments have not recovered to ≤CTCAE grade 1; other toxicities caused by previous antitumor treatments that are expected to be unresolved and have long-term persistent sequelae, such as neurotoxicity caused by platinum-based treatments, are allowed to be included;\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* Known history of drug abuse that cannot be quit, mental disorders, alcoholism, drug abuse, or substance abuse;\n* Known allergy to study drugs or excipients, known severe allergic reactions to any monoclonal antibody;\n* As judged by the investigator, there are factors that seriously endanger the safety of the participants or other factors that may lead to the forced termination.",{"count":57,"type":23},60,[59],"PHASE2","Immunotherapy combined with chemotherapy has emerged as the standard of care for patients with extensive-stage small cell lung cancer (ES-SCLC). The incorporation of thoracic radiotherapy can enhance treatment efficacy. Currently, the main types of research investigating immunotherapy combined with thoracic radiotherapy for untreated ES-SCLC are concurrent radiotherapy and sequential radiotherapy. The aim of this study is to evaluate the efficacy of adebelizumab in combination with chemotherapy, when administered concurrently with radiotherapy versus sequentially with radiotherapy, as a first-line treatment for ES-SCLC.",[62,31,63,30],"SCLC, Extensive Stage","Chemotherapy","2026-08-13",{"date":37,"type":40},{"date":67,"type":40},"2025-01-07",{"date":69,"type":23},"2028-01-31",{"name":71,"class":47},"Peking University Cancer Hospital & Institute",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":79,"targetDuration":4,"studyType":24,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":48},"100575725","phase-2-dietary-supplements-to-treat-radiation-induced-rectal-injury-100575725","NCT06776016","Dietary Supplements to Treat Radiation-Induced Rectal Injury","A Prospective, Single-Arm, Single-Center Study of Dietary Supplements in the Treatment of Radiation-Induced Rectal Injury","Inclusion Criteria:\n\n* Age 18-75 years\n* At least 3 months since the completion of pelvic radiotherapy\n* No evidence of tumor recurrence or metastasis\n* Rectal bleeding with grade 1-2 by LENT-SOMA scales\n\nExclusion Criteria:\n\n* Acute or chronic infectious diseases\n* Serious systemic diseases\n* Known allergies to any components of the study medication\n* Colonoscopy indicating rectal ulceration (\\>1cm2), fistula, stricture, or necrosis\n* Late complications related to pelvic radiation injury\n* Other hemorrhagic or coagulation disorders\n* Previous rectal resection\n* Bowel obstruction or perforation that require surgery\n* Cognitive or psychological disorder",{"count":80,"type":23},33,[59],"This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as dietary supplements in the treatment of chronic radiation-induced rectal injury (RRI). We hypothesize that these supplements will help improve rectal bleeding symptoms and elevate the quality of life for patients. The study will test whether the supplements can lower the LENT-SOMA scales of rectal bleeding and enhance overall patient health. Efficacy will be evaluated through blood tests and other non-invasive methods, ensuring patient safety and comfort throughout the study.",[30,84],"Radiation Proctitis",[34,86,87,88,89],"radiation proctitis","tributyrin","rectal bleeding","butyrate","2026-08-04",{"date":92,"type":40},"2026-08-07",{"date":94,"type":40},"2025-01-15",{"date":96,"type":23},"2026-12-31",{"name":98,"class":47},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":48},"100650197","quantitative-marrow-imaging-marrow-reserve-and-clinical-outcomes-in-patients-undergoing-radiotherapy-for-hematologic-and-related-disorders-100650197","NCT07743476","Quantitative Marrow Imaging, Marrow Reserve, And Clinical Outcomes In Patients Undergoing Radiotherapy For Hematologic And Related Disorders","Inclusion Criteria\n\n* Undergoing or previously underwent radiotherapy at The University of Texas MD Anderson Cancer Center for hematologic or related disorders.\n* Available clinical, imaging, laboratory, treatment, and\u002For outcome data relevant to study objectives.\n* Ability to provide informed consent for prospective participation, when applicable.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n* Inability to provide informed consent, or when applicable, the absence of a legally authorized representative able to provide consent for prospective participation.\n* Insufficient clinical information available to support study objectives.\n* Pregnant women",{"count":106,"type":23},1000,"OBSERVATIONAL","To create a registry for people who are undergoing or previously underwent radiotherapy for hematologic or related disorders.",[110,111,112,30,113],"Quantitative Marrow Imaging","Marrow Reserve","Clinical Outcomes","Hematologic","NOT_YET_RECRUITING","2026-07-30",{"date":90,"type":40},{"date":118,"type":23},"2027-01-23",{"date":120,"type":23},"2038-12-31",{"name":122,"class":47},"M.D. Anderson Cancer Center",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":24,"phases":132,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100650016","phase-2-targeted-induction-therapy-for-stage-iii-unresectable-egfr-mutant-positive-nsclc-100650016","NCT07742332","Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC","Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC: a Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;\n* At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or\u002Fand EBUS;\n* No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);\n* With the feasibility to receive radical surgery ;\n* Good lung function that could tolerate surgical treatment;\n* Minimum age: 18 years;\n* At least one measurable tumor foci (the longest diameter measured by CT shall be \\> 10 mm);\n* Other major organs shall function well (liver, kidney, blood system, etc.):\n* ECOG PS score shall be 0-1;\n* The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;\n* The patient shall sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;\n* The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \\[≥ Grade II specified by New York Heart Association (NYHA)\\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;\n* The patient is a carrier of HIV;\n* The patient has had or is currently suffering from interstitial lung disease;\n* The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;\n* The patient is allergic to befotertinib or its any excipients;\n* The patient is allergic to bevacizumab or its any excipients;\n* The patient is allergic to platinum-based double chemotherapy or its any excipients;\n* The female patient is in pregnancy or lactation period;\n* There are any conditions under which the investigator considers the patient is not suitable to be enrolled.",{"count":131,"type":23},160,[59],"The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.",[135,136,137,30,63],"EGFR","NSCLC (Non-small Cell Lung Cancer)","Locally Advanced Non-Small Cell Lung Cancer",[63,135,139,34,137],"NSCLC (non-small cell lung cancer)","2026-07-29",{"date":142,"type":40},"2026-08-03",{"date":144,"type":40},"2025-11-25",{"date":146,"type":23},"2032-11-25",{"name":148,"class":47},"Peng Zhang",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100648641","comparison-between-virtual-vs-in-person-on-treatment-follow-up-visits-of-radiotherapy-100648641","NCT07724548","Comparison Between Virtual vs in Person on Treatment Follow-up Visits of Radiotherapy","Transforming On-Treatment Follow-Up Care: A Randomized Controlled Trial of Virtual Versus In-Person Visits Evaluating Clinical Outcomes, Patient-Reported Measures, and Telehealth Implementation","Inclusion Criteria:\n\n1. Patients who are 18 years and above.\n2. All patients who are undergoing radiotherapy (\\>5 fractions).\n3. Capacity to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Patients below 18 years\n2. Unable to provide informed consent for participation in the study.",{"count":22,"type":23},"This study aims to evaluate the logistical feasibility and implementation of virtual versus in-person on-treatment follow up visits in a high-volume radiation oncology setting. It further seeks to assess and compare patient and physician satisfaction with both modalities through structured survey data, providing insight into the clinical utility, communication quality, and overall acceptability of telehealth integration during active cancer treatment.",[30],"2026-07-23",{"date":161,"type":40},"2026-07-24",{"date":163,"type":40},"2026-05-11",{"date":165,"type":23},"2026-10-15",{"name":167,"class":47},"Shaukat Khanum Memorial Cancer Hospital & Research Centre",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094","NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years;\n2. Histologically or cytologically confirmed SCLC;\n3. No malignant pleural effusion or pericardial effusion;\n4. No prior history of thoracic radiotherapy or thoracic surgery;\n5. No prior systemic anti-tumor therapy;\n6. ECOG performance status 0-2, with a life expectancy of ≥12 weeks;\n7. At least one measurable lesion per RECIST 1.1 criteria;\n8. No history of interstitial pneumonia;\n9. No history of immune-related pneumonitis;\n10. No history of autoimmune diseases;\n11. No history of significant active pulmonary infection;\n12. No use of corticosteroid therapy within 14 days prior to enrollment;\n13. No Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n14. No brainstem metastases and no significant neurological symptoms;\n15. For subjects with coexisting HBV\u002FHCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy;\n16. All subjects have provided written informed consent;\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment;\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment);\n3. Prior history of thoracic radiotherapy or thoracic surgery;\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n5. Hypersensitivity to adebrelimab;\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy;\n7. Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above;\n8. Presence of pleural effusion or pericardial effusion;",{"count":176,"type":23},43,[59],"This study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy for up to two years, in subjects with extensive-stage small cell lung cancer (ES-SCLC). Additionally, immunohistochemical detection of the expression levels of four key transcriptional proteins-YAP1, NEUROD1, ASCL1, and POU2F3-will be performed to guide the molecular subtyping of SCLC. Based on these findings, we will explore the differential therapeutic outcomes of this regimen across distinct molecular subtypes (A\u002FN\u002FP\u002FY\u002FI\u002FAN\u002FQN), with the goal of identifying the subject population most likely to benefit from this treatment modality, thereby optimizing clinical decision-making.",[180,30],"Lung","2026-07-20",{"date":183,"type":40},"2026-07-22",{"date":185,"type":23},"2026-07-21",{"date":187,"type":23},"2028-01-01",{"name":189,"class":47},"Jiangmen Central Hospital",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":198,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":201,"conditions":202,"keywords":215,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100645943","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100645943","NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE",{"count":200,"type":23},115,"The investigators therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[203,204,205,206,207,208,209,63,30,210,211,212,213,214],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[216,217,218],"Comparative","observational","retrospective","2026-07-13",{"date":221,"type":40},"2026-07-15",{"date":223,"type":23},"2026-07-10",{"date":225,"type":23},"2026-08-20",{"name":227,"class":47},"University Hospital, Grenoble",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":48},"100646636","phase-3-anti-pcsk9-antibody-tafolecimab-and-anti-pd-1-antibody-sintilimab-combined-with-neoadjuvant-chemoradiotherapy-for-pmmr-mss-locally-advanced-rectal-cancer--a-prospective-multicenter-randomized-open-label-parallel-controlled-trial-100646636","NCT07686796","Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR\u002F MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial","Inclusion Criteria:\n\n1. Age 18 to 75 years, any sex.\n2. Histologically confirmed rectal adenocarcinoma, determined to be pMMR (proficient mismatch repair) or MSS (microsatellite stable) by immunohistochemistry and\u002For genetic testing; clinical stage cT3\u002FT4 or cN+; distal tumor margin ≤ 12 cm from the anal verge; and eligible for surgical resection.\n3. No evidence of distant metastases.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n5. Adequate hematologic and biochemical function: absolute neutrophil count ≥ 1.5 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL, platelets ≥ 100 × 10⁹\u002FL, ALT\u002FAST ≤ 2.5 times the upper limit of normal (ULN), creatinine ≤ 3.0 × ULN.\n6. Anticipated good compliance and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Known allergy or severe adverse reaction to any study drug, including tafolecimab, PD-1 inhibitor (sintilimab), capecitabine, oxaliplatin, or any excipients.\n2. Rectal cancer confirmed as dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high).\n3. Pregnant or breastfeeding women, or patients of childbearing potential who refuse to use effective contraception during the study.\n4. Other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, papillary thyroid carcinoma, or other malignancies considered cured after adequate treatment.\n5. Prior anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, immunotherapy, or local surgical excision.\n6. Previous treatment with a PCSK9 inhibitor for any indication.\n7. Severe or uncontrolled neurological disease, psychiatric disorder, or cognitive impairment that, in the investigator's judgment, would affect informed consent or protocol adherence.\n8. Severe cardiovascular or cerebrovascular disease, including but not limited to: unstable angina, myocardial infarction, coronary revascularization, or stroke within 6 months before enrollment; clinically significant arrhythmia requiring treatment or left ventricular ejection fraction (LVEF) \\\u003C 50%; New York Heart Association (NYHA) class III or IV heart failure.\n9. Active infection requiring long-term systemic therapy (e.g., antibiotics, antivirals, or antifungals).\n10. Active autoimmune disease, or requirement for long-term systemic immunosuppressive therapy or corticosteroids (at a dose equivalent to prednisone \\> 10 mg\u002Fday).\n11. Known history of human immunodeficiency virus (HIV) infection, or active syphilis, or active pulmonary tuberculosis.\n12. Active hepatitis B (HBsAg positive and HBV DNA \\> 200 IU\u002FmL or \\> 1000 copies\u002FmL) or active hepatitis C (HCV RNA positive).\n13. Any other clinical condition that, in the investigator's opinion, could interfere with study assessments, increase treatment risk, or lead to premature study discontinuation (including but not limited to severe alcohol or drug abuse).",{"count":235,"type":23},148,[26],"This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab (an anti-PD-1 inhibitor) versus neoadjuvant chemoradiotherapy combined with sintilimab alone in patients with pMMR\u002FMSS locally advanced rectal cancer. The primary endpoint is the complete response (CR) rate, including the pathological complete response (pCR) rate in patients who undergo surgery after neoadjuvant therapy, and the clinical complete response (cCR) rate in patients managed with a watch-and-wait strategy. Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), downstaging rate, R0 resection rate, tumor regression grade, sphincter preservation rate, disease-free survival (DFS), overall survival (OS), and safety.",[29,239,240,241,30,242,243],"PD-1 Inhibitor","PCSK9 Inhibitor","RCT","Capecitabine","Oxaliplatin","2026-07-06",{"date":246,"type":40},"2026-07-07",{"date":248,"type":23},"2027-01-01",{"date":250,"type":23},"2035-01-01",{"name":252,"class":47},"Guangdong Provincial People's Hospital",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":198,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100471333","phase-3-a-randomized-trial-of-five-fraction-partial-breast-irradiation-rapid2-100471333","NCT05417516","A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)","A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)","Inclusion Criteria:\n\nFor inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease (see AJCC TNM Cancer Staging, Appendix II).\n2. Treated by BCS with microscopically clear resection margins \\>= 1mm for invasive and non-invasive disease or no residual disease on re-excision.\n3. Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection or clinical assessment with a negative axillary ultrasound and\u002For biopsy, for women with unifocal tumours \\\u003C= 2cm, histologic grade 1 or 2, ER or PR+ and HER2-ve that are being planned for endocrine therapy\n\nExclusion Criteria:\n\nPatients who satisfy any of the following exclusion criteria are NOT eligible for this study:\n\n1. Age less than 50 years.\n2. Known to be BRCA 1 and\u002For BRCA 2 positive.\n3. Tumour size \\>3cm in greatest diameter on pathological examination.\n4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \\\u003C= 3cm remain eligible\n5. Evidence of a DCIS component \\> 3cm\n6. Lobular carcinoma only.\n7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible).\n8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible).\n9. History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma.\n10. Known pregnancy or currently lactating.\n11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma).\n12. Inability to plan the patient for the experimental technique.","50 Years","120 Years",{"count":263,"type":23},910,[26],"The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.",[267,30,268],"Breast Neoplasm Female","Cosmetic Outcome","2026-07-03",{"date":246,"type":40},{"date":272,"type":40},"2023-11-20",{"date":274,"type":23},"2031-11",{"name":276,"class":47},"Ontario Clinical Oncology Group (OCOG)",30,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":48},"100644128","real-world-study-on-the-efficacy-safety-and-prognostic-factors-of-immune-checkpoint-inhibitors-combined-with-radiotherapy-in-patients-with-malignant-tumors-a-prospective-non-interventional-clinical-study-100644128","NCT07665736","Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Histologically or cytologically confirmed malignant tumor;\n3. Planned to receive immunotherapy combined with radiotherapy as the basis of treatment;\n4. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);\n5. Adequate organ function (reference may be made to laboratory test indicators, such as routine blood tests, liver and kidney function);\n6. Voluntarily participate in this study, sign the informed consent form, and agree to comply with follow-up.\n\nExclusion Criteria:\n\n1. Patients with severe cognitive impairment, mental illness, or other conditions that, in the judgment of the investigator, preclude them from cooperating with participation in this study;\n2. Active, uncontrolled serious infection, or known human immunodeficiency virus (HIV) infection;\n3. Pregnant or breastfeeding women;\n4. Any unstable systemic disease (including but not limited to severe cardiac, hepatic, or renal insufficiency).",{"count":285,"type":23},200,"Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly. Radiotherapy can induce massive tumor cell death in a short period and expose abundant tumor-specific antigens, turning the irradiated tumor into an endogenous tumor vaccine and even causing regression or disappearance of non-irradiated tumors (the abscopal effect) . Preclinical studies have shown that stereotactic body radiotherapy (SBRT) combined with PD-1\u002FPD-L1 inhibitors can activate systemic immunity, sensitize tumor-specific T cells to enter the bloodstream, and enable their homing to distant tumors, thereby inhibiting the growth of non-irradiated tumors . However, conclusions from rigorous randomized controlled trials have limitations when applied to the complex and heterogeneous patient populations in real-world settings. Real-world research is increasingly valued globally to complement traditional clinical trial evidence. This project prospectively collects data from patients receiving immunotherapy combined with radiotherapy in real-world clinical practice, which is of great value for evaluating long-term efficacy, safety, and impact on quality of life, and can provide high-level evidence for optimizing clinical practice and informing healthcare decisions.",[30,288],"Immune Checkpoint Inhibitors (ICIs)","2026-06-19",{"date":291,"type":40},"2026-06-24",{"date":293,"type":23},"2026-06-30",{"date":295,"type":23},"2029-06-15",{"name":297,"class":47},"Sichuan University",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":48},"100619043","phase-2-intestinal-low-dose-radiotherapy-plus-immunochemotherapy-for-conversion-of-borderline-resectableunresectable-esophageal-squamous-cell-carcinoma-100619043","NCT07339488","Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","ILDR-03","Inclusion Criteria:\n\n1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.\n2. Age ≥18 years and ≤75 years; both sexes are eligible.\n3. ECOG performance status score of 0-1.\n4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.\n5. Thoracic esophageal cancer.\n6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.\n7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.\n8. Baseline laboratory requirements (within 7 days prior to enrollment):\n\n   Hematology:\n   1. Hb≥90 g\u002FL (no transfusion within 14 days)\n   2. NEUT ≥1.5×10⁹\u002FL\n   3. PLT ≥100×10⁹\u002FL\n   4. WBC≥3×10⁹\u002FL\n\n   Biochemistry:\n   1. ALT and AST≤2.5×ULN\n   2. TBIL≤1.5×ULN\n   3. SCr≤1.5×ULN; or CrCl≥60 mL\u002Fmin Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3\u002FFT4 levels should also be considered; eligible if FT3\u002FFT4 are normal) Echocardiography: LVEF≥50%\n9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.\n10. No psychological, familial, social, or geographical factors that may impair protocol adherence.\n11. Other parameters meet general clinical trial enrollment criteria.\n12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases other than supraclavicular lymph node metastases.\n2. Presence or high risk of esophageal perforation.\n3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.\n4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.\n5. Patients with a history of thoracoabdominal\u002Fpelvic radiotherapy within 6 months prior to enrollment.\n6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).\n7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.\n8. Respiratory depression, airway obstruction, or tissue hypoxia.\n9. Severe cardiac disease (i.e., NYHA functional class II or higher).\n10. Markedly abnormal liver or kidney function (i.e., indicators \\>3 times the upper limit of normal).\n11. Active hepatitis B, hepatitis C, HIV, or syphilis.\n12. Active brain disease or central nervous system\u002Fmeningeal metastases with significant symptoms, or impaired decision-making capacity.\n13. Hypersensitivity to drugs included in the trial.\n14. Drug and\u002For alcohol abuse.\n15. Pregnant or lactating women.\n16. Concurrent participation in another therapeutic clinical trial.\n17. Major surgical procedure within 30 days prior to enrollment.\n18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.",{"count":176,"type":23},[59],"Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.\n\nCurrent conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.\n\nRetrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.\n\nBased on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR\u002FUR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR\u002FUR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg\u002Fm² on day 1), cisplatin (75 mg\u002Fm² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.",[310,311,312,313,63,30,314],"Borderline Resectable Carcinoma","Unresectable Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Immune Checkpoint Inhibitor","Tislelizumab","2026-06-17",{"date":317,"type":40},"2026-06-18",{"date":319,"type":40},"2025-12-05",{"date":321,"type":23},"2028-11-01",{"name":323,"class":47},"Chuangzhen Chen",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":331,"sex":18,"minAge":332,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":48},"100642071","effect-of-the-miroki-companion-robot-on-anxiety-in-pediatric-radiotherapy-100642071","NCT07645950","Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy","KOKORO01","Inclusion Criteria:\n\n1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years.\n2. Child with an indication for radiotherapy treatment at ICM.\n3. Child who speaks French.\n4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent.\n5. Child covered by the French national health insurance system.\n\nExclusion Criteria:\n\n6\\. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria\n\n1. Parent of a child enrolled in the study.\n2. Able to speak French.\n3. Willing to participate in the study. Parent Exclusion Criteria\n\n1\\. Parents or legal representatives under legal protection, or presenting an inability to consent or to understand the study information, making it impossible to provide free and informed consent for the minor's participation.",true,"4 Years",{"count":334,"type":23},6,"Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal\u002Freversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.",[337,30,338],"Pediatric Oncology","Parent","2026-06-09",{"date":341,"type":40},"2026-06-12",{"date":343,"type":23},"2026-07",{"date":345,"type":23},"2027-07",{"name":347,"class":47},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":48},"100641725","phase-2-different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc-100641725","NCT07646639","Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC","Different-Dose Short-Course Radiotherapy Plus CAPOX, Anti-PD-1 Antibody and Interleukin-2 for Locally Advanced Rectal Cancer: A Single-Centre, Prospective, Randomised Phase II Trial","PRIDE-02","Inclusion Criteria:\n\n1. Male and female patients aged 18 to 70 years.\n2. Histologically confirmed rectal adenocarcinoma with the distal margin of the tumor located within 12 cm of the anal verge.\n3. MRI-based clinical stage T3-T4 or any T with lymph node-positive (N+) disease.\n4. Adequate hematologic, hepatic, and renal function defined as: absolute neutrophil count \\>=1.5 x 10\\^9\u002FL; platelet count \\>=75 x 10\\^9\u002FL; serum total bilirubin \\\u003C=1.5 x upper normal limit (UNL); aspartate aminotransferase \\\u003C=2.5 x UNL; alanine aminotransferase \\\u003C=2.5 x UNL; serum creatinine \\\u003C=1.5 x UNL.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n\nExclusion Criteria:\n\n1. Metastatic disease (Stage IV).\n2. Recurrent rectal cancer.\n3. Concurrent active bleeding, perforation, or other complicated conditions requiring emergency surgery.\n4. Prior systemic anticancer therapy for rectal cancer.\n5. Presence of another non-colorectal neoplastic disease at the same time.\n6. Patients with any active autoimmune disease or a history of autoimmune disease requiring steroids or immunomodulatory therapy.\n7. Patients with interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes mellitus, hypertension, pulmonary fibrosis, and acute pneumonitis).\n8. Any unresolved grade \\>=2 toxicity (according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) resulting from previous treatment, except for anemia, alopecia, and skin hyperpigmentation.\n9. Prior treatment with anti-programmed death-1 (PD-1)\u002FPD-L1 antibody or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.\n10. Pregnant or breastfeeding women.\n11. Known or tested positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).\n12. Known or suspected history of allergy to any of the relevant drugs used in the study.","70 Years",{"count":358,"type":23},122,[59],"This prospective, randomized phase II trial is designed to evaluate whether low-dose short-course radiotherapy differs from common-dose short-course radiotherapy in terms of efficacy when both regimens are sequentially combined with CAPOX, a PD-1 monoclonal antibody, and interleukin-2 (IL-2) in patients with locally advanced rectal cancer. The study is based on findings from our previous single-center, single-arm PRIDE01 study, in which neoadjuvant short-course radiotherapy followed by systemic chemoimmunotherapy and IL-2 demonstrated encouraging antitumor activity relative to historical short-course radiotherapy-based approaches. The current trial aims to provide more robust clinical evidence regarding the potential role of low-dose radiotherapy combined with IL-2 as a sensitization strategy in multimodal neoadjuvant therapy. By comparing complete response rates between the two radiotherapy dose levels, this study may help define an optimized neoadjuvant approach and support future organ-preservation strategies for patients with locally advanced rectal cancer.",[362,30],"Rectal Cancer",[31,364,365],"IL-2","Short-course radiotherapy",{"date":367,"type":40},"2026-06-15",{"date":369,"type":40},"2026-05-20",{"date":371,"type":23},"2030-12-31",{"name":373,"class":47},"The First Affiliated Hospital with Nanjing Medical University",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":48},"100621659","patient-position-monitoring-system-for-beam-gated-radiation-therapy-of-malignancies-of-the-chest-and-upper-abdomen-100621659","NCT07373496","Patient Position Monitoring System for Beam Gated Radiation Therapy of Malignancies of the Chest and Upper Abdomen","Pilot Study of a Novel Patient Position Monitoring System for Beam Gated Radiation Therapy of Malignancies of the Chest and Upper Abdomen","Eligibility Criteria\n\n* Planning to receive a course of radiation therapy that, per the treating radiation oncologist, requires motion management at the time of CT simulation and during treatment. Types of treatments that require motion management during radiation therapy include treatments to the lung, heart, breast, and upper abdomen (pancreas, liver, adrenals). These may include either free-breathing treatments or breath-hold treatments.\n* At least 18 years of age.\n* No documented allergy to medical grade adhesives.\n* Able to understand and willing to sign an IRB approved written informed consent document.",{"count":382,"type":23},20,"This study will evaluate the feasibility of using this novel patient position monitoring system for patients receiving radiation therapy to targets involving the chest or upper abdomen, as these are the most affected by respiratory motion. This motion monitoring system will be incorporated with standard of care on-board CT imaging to confirm that the respiratory position is tracking the tumor target appropriately.",[30,385],"Radiotherapy, Image-Guided",[30,387,388],"Cancer","Motion","2026-05-21",{"date":391,"type":40},"2026-05-22",{"date":369,"type":40},{"date":394,"type":23},"2027-06-30",{"name":396,"class":47},"Washington University School of Medicine",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":425},"100577984","phase-2-timely-integration-of-palliative-care-in-oncology-care-for-patients-referred-for-palliative-radiotherapy-on-bone-metastases-a-randomized-trial-100577984","NCT06805396","Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial","Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial (TIPZO-RT Trial)","TIPZO-RT","Inclusion Criteria:\n\n1. broad informed consent for PRESENT+ (i.e., consent for filling out questionnaires at regular intervals and randomization into future intervention studies), and\n2. having their treating physician in the TIPZO-RT study site (UMC Utrecht, Radboudumc or LUMC).\n\nExclusion Criteria:\n\n1. not able to understand the objective of the study (in Dutch),\n2. cognitive impairment or dementia, and\n3. has been in contact with palliative care consultants of the hospital PCCT before.",{"count":406,"type":23},246,[59],"Rationale: With improvements in systemic tumour-directed treatments for primary tumours, survival rates for patients with bone metastases are improving. However, individual illness trajectories become less predictable and more vulnerable to adverse events from treatments, negatively impacting a patient's quality of life (QoL). Palliative care is aimed at reducing symptoms and improving QoL for patients with incurable diseases through early identification, thorough assessment, and effective management of physical, psychological, social, and spiritual challenges. Early integration of specialist palliative care into oncology care has shown to reduce symptom burden and potentially inappropriate end-of-life care, and to enhance QoL, yet it is often initiated late.\n\nObjective: The primary objective is to evaluate the satisfaction with care and QoL experienced by patients with bone metastases who are offered a consultation with the hospital palliative care consultation team (PCCT) when referred for palliative radiotherapy compared to patients who receive standard of care.\n\nStudy design: A prospective, pragmatic, two-arm multicenter randomized controlled trial within the PRospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT+) cohort that follows the Trials within Cohorts (TwiCs) design.\n\nStudy population: Patients with bone metastases referred for palliative radiotherapy who have their treating physician in one of the participating centers and have not been in contact with the hospital PCCT before.\n\nIntervention: A consultation with the hospital PCCT within two weeks after inclusion in PRESENT+. In the standard of care control group, no consultation with the PCCT will be scheduled. They may have a consultation during follow-up if referring physicians may consider a consultation appropriate, or when patients themselves feel they want a referral.\n\nMain study parameters\u002Fendpoints: Satisfaction with care (affective behavior) four weeks after inclusion in PRESENT+.",[410,30],"Bone Metastases in Subjects With Advanced Cancer",[412,413,30,414,415,416],"Palliative Care","Bone Metastases","Advanced Cancer","Quality of Life","Quality of Care",{"date":418,"type":40},"2026-05-12",{"date":420,"type":40},"2025-06-02",{"date":422,"type":23},"2027-01-31",{"name":424,"class":47},"Roxanne Gal",5,{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":48},"100601652","phase-3-a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally-advanced-rectal-cancer-100601652","NCT07113275","A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer","A National Multicenter, Randomized, Placebo-Controlled Phase III Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Patients or their family members agree to participate in the study and sign the informed consent form;\n2. Age 18-75 years, male or female;\n3. Histologically confirmed Locally Advanced rectal adenocarcinoma;\n4. Immunohistochemistry and\u002For genetic testing confirmed pMMR\u002FMSS;\n5. inferior margin ≤ 10 cm from the anal verge;\n6. ECOG performance status score is 0-1;\n7. Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc;\n8. There was no operative contraindication;\n9. Laboratory tests were required to meet the following requirements: white blood cell (WBC) ≥ 4×109\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; Platelet count ≥ 100×109\u002FL; Hemoglobin ≥90 g\u002FL; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50 mL\u002Fmin; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;\n10. Urinary protein \\\u003C 2+ or 24-hour urinary protein excretion \\\u003C 1 g at baseline.\n\nExclusion Criteria:\n\n1. Patients with MSI-H\u002FdMMR LARC；\n2. Subjects who have previously received any form of immunotherapy, including but not limited to immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or any other treatment targeting tumor immunomodulatory mechanisms;\n3. Presence of any concurrent disease, condition (including laboratory abnormality), history of substance abuse, or current evidence thereof, which, in the judgment of the Investigator, may compromise subject safety, interfere with the process of obtaining informed consent, affect subject compliance, or confound the safety assessment of the investigational product(s).",{"count":434,"type":23},444,[26],"This study is a national multicenter, prospective randomized, placebo- controlled Phase III clinical trial designed to investigate the potential therapeutic benefit of immunotherapy combined with total neoadjuvant therapy (TNT) and to compare the efficacy of different radiotherapy modalities followed by immunotherapy.",[362,438,30,31],"Total Neoadjuvant Therapy","2026-05-10",{"date":441,"type":40},"2026-05-13",{"date":443,"type":23},"2026-05-15",{"date":445,"type":23},"2028-12-31",{"name":447,"class":47},"Tao Zhang",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":198,"minAge":454,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":458,"briefSummary":460,"conditions":461,"keywords":466,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":4},"100637766","effects-of-moderate-intensity-interval-aerobic-exercise-miiae-on-inflammatory-immune-metabolic-physical-fitness-and-quality-of-life-parameters-in-breast-cancer-patients-undergoing-radiotherapy-100637766","NCT07583719","Effects of Moderate-intensity Interval Aerobic Exercise (MIIAE) on Inflammatory, Immune, Metabolic, Physical Fitness, and Quality of Life Parameters in Breast Cancer Patients Undergoing Radiotherapy.","Inclusion Criteria:\n\n* Women aged between 20 and 65 years.\n* Clinical diagnosis of breast cancer (Stage I-III).\n* Patients who have undergone lumpectomy or mastectomy.\n* Scheduled to start radiotherapy treatment.\n* Sedentary lifestyle according to international physical activity guidelines.\n* Ability to understand and follow instructions.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of infectious disease.\n* Cardiovascular or respiratory disease.\n* Metastatic disease.\n* Uncontrolled diabetes mellitus.\n* Neuropathy.\n* Physically active individuals meeting WHO physical activity recommendations.\n* Participation in an exercise intervention program within the last 3 months.\n* Any condition that, in the opinion of the research team, may compromise safety or participation.","20 Years","65 Years",{"count":457,"type":23},40,[459],"NA","Breast cancer and its treatment with radiotherapy may be associated with systemic inflammatory, hematological, cardiac, body composition, functional and quality-of-life alterations. Exercise has emerged as a non-pharmacological strategy with potential benefits during oncological treatment; however, further evidence is needed regarding the effects of supervised moderate-intensity interval aerobic exercise during radiotherapy.\n\nThis randomized controlled trial aims to evaluate the effects of a supervised moderate-intensity interval aerobic exercise programme on systemic inflammatory and immune-derived hematological indices, cardiac biomarkers, body composition, muscle strength, lower-limb power, sleep quality and breast cancer-specific quality of life in women with breast cancer undergoing radiotherapy.\n\nParticipants will be allocated to either an experimental group performing supervised moderate-intensity interval aerobic exercise during radiotherapy or to a control group receiving usual care without structured exercise during the study period. Outcomes will be assessed at baseline and after completion of the intervention period.",[30,462,463,464,465],"Inflamation","Immune System","Physical Fitness","Breast Cancer",[467,468,469,415,470,465,471,472],"Interval Training","Inflammation","Body Composition","Immune function","Sleep","oncology rehabilitation","2026-05-06",{"date":441,"type":40},{"date":476,"type":23},"2026-06-01",{"date":96,"type":23},{"name":479,"class":47},"Universidad Francisco de Vitoria",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":499,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":48},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":488,"type":23},400,[59,26],"This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[362,492,493,30,63,494,495,496,497,498,415],"Total Neoadjuvant Treatment","Neoadjuvant Therapy","Organ Preservation","Radiotherapy Side Effect","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome",[500,492,501,30,63,497,494,495,502,503,504,505,498],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications",{"date":163,"type":40},{"date":508,"type":40},"2025-01-06",{"date":510,"type":23},"2029-12-27",{"name":512,"class":47},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":533},"100511615","phase-3-ic-plus-low-dose-radiation-plus-cadonilimab-in-lanpc-100511615","NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy, radiotherapy or immunotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 9g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Distant metastases;\n* Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Pregnancy or lactation;\n* Have uncontrolled cardiovascular disease;\n* Severe complication, eg, uncontrolled hypertension;\n* Mental disorder;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts.",{"count":521,"type":23},380,[26],"This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.",[525,313,30,63],"Nasopharyngeal Carcinoma",{"date":163,"type":40},{"date":528,"type":40},"2024-01-10",{"date":530,"type":23},"2029-12",{"name":532,"class":47},"Sun Yat-sen University",3,{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":356,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":48},"100597712","phase-2-bits-to-hcc-study-haiciparomlimabtuvonralimab--bevacizumab--sbrt-for-bclc-c-hcc-with-pvtt-andor-oligometastases-100597712","NCT07062055","BITS-TO-HCC Study: HAIC+Iparomlimab\u002FTuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and\u002For Oligometastases","Bevacizumab Plus Iparomlimab\u002FTuvonralimab With Hepatic Artery Infusion Chemotherapy Followed by Stereotactic Body Radiotherapy in Patients With BCLC Stage C Hepatocellular Carcinoma With Thrombus and\u002For Extrahepatic Oligometastases (BITS-TO-HCC): Study Protocol of a Prospective, Single- Center, Single-Arm, Phase II Study","Inclusion Criteria:\n\n1. Male or female patients aged between 18 and 70 years.\n2. Unresectable HCC, BCLC Stage C according to the BCLC strategy-2025 update, with staging established via biopsy pathology and\u002For clinical diagnosis.\n3. Child-Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n4. Metastatic burden and SBRT eligibility\n\n   * Extrahepatic oligometastatic disease defined as ≤3 involved organs with ≤5 total metastatic lesions\n   * All intended intrahepatic and\u002For extrahepatic SBRT targets must satisfy protocol-specified target-coverage, liver reserve, and organ-at-risk (OAR) constraints within a composite 5-fraction plan\n5. Prognosis \\& measurable disease\n\n   * Life expectancy ≥3 months\n   * ≥1 measurable lesion (per RECIST 1.1):\n   * Tumor: ≥10 mm (CT long axis)\n   * Lymph node: ≥15 mm (CT short axis)\n6. Prior therapy\n\n   * Prior locoregional therapy permitted：radiofrequency ablation (RFA), TACE, or HAIC, provided that:\n   * Documented radiographic progression or intolerance after the prior therapy\n   * Washout ≥28 days\n   * Treatment-related toxicities recovered to ≤Grade 1 (alopecia and peripheral neuropathy ≤Grade 2 allowed)\n7. Laboratory and virologic requirements\n\n   * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5 × upper limit of normal (ULN); total bilirubin ≤3 × ULN; serum albumin ≥28 g\u002FL\n   * Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL\u002Fmin\n   * Urine dipstick protein \\\u003C2+; if baseline dipstick proteinuria is ≥2+, 24-hour urinary protein must be \\\u003C1 g\n   * International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN\n\nExclusion Criteria:\n\n1. Histopathological exclusions\n\n   * Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components\n2. Curative local therapy candidacy\n\n   * Current candidacy for resection, liver transplant, or RFA\n3. RT infeasibility\n\n   * Prior radioembolization\n   * Single liver tumor ≥15 cm or total intrahepatic tumor diameter ≥20 cm\n   * more than 5 discrete intrahepatic parenchymal foci are present\n   * direct tumor extension into the stomach, duodenum, small bowel, or large bowel\n   * measurable common or main-branch biliary duct involvement\n   * Prior liver radiotherapy that would result in excessive overlap with the planned treatment fields\n4. Prior systemic therapies\n\n   * Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs))\n   * Prior immunotherapy: anti-PD-(L)1\u002FCTLA-4 or chimeric antigen receptor T-cell therapy\n5. Hemorrhage\u002Fportal hypertension and hepatic decompensation risk\n\n   * Variceal bleeding within 6 months.\n   * Untreated or high-risk esophagogastric varices (e.g., grade ≥2 on endoscopy within 3 months) or other clinical evidence of portal hypertension with high bleeding risk per investigator.\n   * Moderate or severe ascites\n   * History of or active hepatic encephalopathy\n   * History of hemoptysis (≥2.5 mL of bright red blood per episode) within 28 days before study treatment\n   * Evidence of bleeding diathesis or significant coagulopathy\n   * Current or recent (within 10 days before study treatment) use of aspirin (≥325 mg\u002Fday), dipyridamole, ticlopidine, clopidogrel, cilostazol, or therapeutic-dose oral\u002Fparenteral anticoagulants or thrombolytic agents\n6. Allergy to any component of iparomlimab\u002Ftuvonralimab or bevacizumab\n7. Comorbidities\n\n   * Active autoimmune disease or a history of autoimmune or inflammatory disease that may relapse; exceptions include hypothyroidism controlled with hormone replacement only, controlled celiac disease, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia)\n   * Any condition requiring systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressive medication within 14 days before study treatment\n   * Active or uncontrolled infection, including tuberculosis, or known HIV infection\n   * Prior allogeneic stem cell transplantation or organ transplantation\n   * Inadequately controlled hypertension, defined as systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure \\>90 mmHg despite optimal medical management, or a history of hypertensive crisis or hypertensive encephalopathy\n   * History within 6 months before study treatment of myocardial infarction, unstable angina, symptomatic heart failure (New York Heart Association class ≥II), cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events\n   * Major surgical procedure within 28 days before study treatment, or serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture\n   * History within 6 months before study treatment of gastrointestinal perforation, abdominal or tracheoesophageal fistula, or intra-abdominal abscess",{"count":542,"type":23},54,[59],"This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab\u002Ftuvonralimab plus bevacizumab followed by stereotactic body radiotherapy (SBRT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) who present with portal vein tumor thrombus (PVTT) or extrahepatic oligometastatic disease. The study aims to determine whether this combination strategy can prolong progression-free survival (PFS), while also improving overall survival (OS), objective response rate (ORR), disease control rate (DCR), and local control rate (LCR), as well as maintaining quality of life (QoL). In addition, the trial will systematically evaluate the safety profile and treatment-related toxicities associated with this regimen.",[546,547,548,30,31,549],"Hepatocellular Carcinoma","Portal Vein Tumor Thrombus","Oligometastases","Hepatic Artery Infusion Chemotherapy","2026-05-04",{"date":552,"type":40},"2026-05-08",{"date":554,"type":40},"2025-07-25",{"date":556,"type":23},"2029-07-25",{"name":46,"class":47},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":331,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":568,"conditions":569,"keywords":580,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":48},"100621015","mrinrt-swansea-university-and-swwcc-collaboration-study-100621015","NCT07365124","MRinRT: Swansea University and SWWCC Collaboration Study.","Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.","MRinRT","Inclusion Criteria for health volunteers:\n\n* Free from medical conditions that could confound imaging or study results\n* Eligible for MRI\n\nInclusion Criteria for patients:\n\n* Confirmed diagnosis of invasive carcinoma at the relevant tumour\u002Ftarget sites listed in this protocol\n* Scheduled to receive radiotherapy to the target site\n* ECOG performance status of 0-2\n* Eligible for MRI (determined through MRI safety screening)\n\nExclusion Criteria:\n\n* Presence of medical conditions that may interfere with study outcomes or data interpretation\n* Use of regular medications that could affect imaging results or safety\n* Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.",{"count":567,"type":23},165,"The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:\n\n* Can MRI scan images be adjusted to make the tumour and normal tissues easier to see?\n* Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise?\n* Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects?\n* Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects?\n\nThis study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:\n\n1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position\u002Fsize\u002Fshape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour\u002Ftarget to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy).\n2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials.\n\nThe study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.",[570,571,30,572,573,574,575,576,577,578,579],"Carcinoma","Glioblastoma","MRI","MRI-guided Adaptive Radiotherapy","MRI Scanner Configuration","MRI Image Enhancement","Oesophageal Carcinoma","Pancreas Carcinoma","Gastric Cancer","Brain (Nervous System) Cancers",[572,30,581,582],"MRI adaptive radiotherapy","MRI Imaging Biomarker","2026-04-29",{"date":585,"type":40},"2026-04-30",{"date":587,"type":23},"2026-05",{"date":589,"type":23},"2032-01",{"name":591,"class":47},"Swansea Bay University Health Board",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":601,"conditions":602,"keywords":607,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":48},"100627052","measuring-fluid-buildup-in-cancer-patients-100627052","NCT07443618","Measuring Fluid Buildup in Cancer Patients","Monitoring of Oedema in Cancer Patients - A Pilot Study","Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving radiotherapy due to breast cancer within the last 6 months\n* Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital\n* Age ≥ 18 years\n* Visible lymphoedema in at least one upper extremity\n\nInclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving chemotherapy due to cancer within the last 2 months\n* Hospitalised in the Oncology Ward at Aalborg University Hospital\n* Estimated length of hospital stay of at least 6 days\n* Age ≥ 18 years\n* Visible peripheral oedema in at least one lower extremity\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women\n* Amputated limb(s)\n* Pacemaker or implanted cardioverter-defibrillator due to risk of interference from the electrical signal\n* Metallic prostheses due to risk of interference with the device signal\n* Inability to lie still for the duration of the measurement interval (minimum 2 minutes at a time)\n* Inability to stand on a scale, i.e. permanently bedridden.\n* Inability to cooperate with urine collection\n* Receiving dialysis\n* Terminal illness",{"count":600,"type":23},46,"The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include:\n\n* Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients)\n* Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized)\n\nParticipants will:\n\n* Have measurements taken using bioelectrical impedance\n* Provide blood samples and 24-hour urine collection\n* Weight monitorering\n* Complete diet and fluid registration (inclusive enteral and parenteral)\n* Have clinical palpatory and measurement assessment of oedema.",[387,603,604,605,63,30,606],"Oedema","Bioelectrical Impedance","Lymphoedema","Fluid Balance",[608,609,610],"Localized oedema in cancer","Bioelectrical impedance","Post radiation lymphoedema","2026-04-28",{"date":583,"type":40},{"date":614,"type":40},"2026-02-01",{"date":616,"type":23},"2026-07-31",{"name":618,"class":47},"Jens Rikardt Andersen",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":625,"targetDuration":627,"studyType":107,"phases":4,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":48},"100636426","establishment-of-a-prospective-clinical-cohort-of-small-cell-lung-cancer-patients-receiving-radiotherapy-involved-comprehensive-treatment-100636426","NCT07565532","Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment","Inclusion Criteria:\n\nInclusion Criteria for Limited-Stage Small Cell Lung Cancer (LS-SCLC):\n\n1\\. Voluntary signed informed consent according to clinical routine practice. 2. Histologically and radiologically confirmed, previously untreated limited-stage SCLC (according to the Veterans Administration Lung Study Group staging system).\n\n3\\. Age ≥ 18 years. 4. Life expectancy ≥ 8 weeks. 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 6. At least one documented efficacy assessment. 7. At least one measurable lesion as confirmed by the investigator according to RECIST (iRECIST 2017) criteria.\n\n8\\. Adequate organ and bone marrow function, with laboratory tests performed within 7 days prior to the first dose meeting the following criteria (without receiving any blood components, hematopoietic growth factors, albumin, or other corrective therapies considered by the investigator within 14 days prior to laboratory assessments):\n\n1. Hematology: Hemoglobin (Hb) ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count (PLT) ≥ 90 × 10⁹\u002FL.\n2. Biochemistry: Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN); serum total bilirubin (TBIL) ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN in patients without liver metastases, or ≤ 5.0 × ULN in patients with liver metastases; serum albumin (ALB) ≥ 25 g\u002FL.\n3. Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for patients receiving prophylactic anticoagulation, the INR and APTT values should be judged by the treating physician or investigator to be within a safe and effective therapeutic range).\n\n9\\. Pulmonary function test showing FEV₁ \\> 0.75 L. 10. No evidence of severe interstitial lung disease confirmed by CT or PET\u002FCT prior to treatment.\n\n11\\. No prior or concurrent primary malignancy at other sites. 12. No requirement for PD-L1 expression level.\n\nInclusion Criteria for Extensive-Stage Small Cell Lung Cancer (ES-SCLC):\n\n1\\. Voluntary signed informed consent according to clinical routine practice. 2. Histologically confirmed SCLC with complete staging workup showing extensive-stage disease (according to the Veterans Administration Lung Study Group staging system).\n\n3\\. Age ≥ 18 years. 4. Life expectancy ≥ 8 weeks. 5. At least one documented efficacy assessment. 6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2. 7. Adequate organ and bone marrow function, with laboratory tests performed within 7 days prior to the first dose meeting the following criteria (without receiving any blood components, hematopoietic growth factors, albumin, or other corrective therapies considered by the investigator within 14 days prior to laboratory assessments):\n\n1. Hematology: Hemoglobin (Hb) ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count (PLT) ≥ 90 × 10⁹\u002FL.\n2. Biochemistry: Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN); serum total bilirubin (TBIL) ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN in patients without liver metastases, or ≤ 5.0 × ULN in patients with liver metastases; serum albumin (ALB) ≥ 25 g\u002FL.\n3. Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for patients receiving prophylactic anticoagulation, the INR and APTT values should be judged by the treating physician or investigator to be within a safe and effective therapeutic range).\n\n8\\. No severe concurrent medical illness. 9. Forced expiratory volume in one second (FEV₁) \\> 0.75 L. 10. For patients with prior radiotherapy to the primary lesion, the current radiotherapy target is limited to metastatic lesions.\n\n11\\. No prior or concurrent primary malignancy at other sites. 12. No requirement for PD-L1 expression level. 13. For patients with limited-stage SCLC who previously received curative-intent treatment, upon recurrence or metastasis, if complete staging workup is available and this is their first use of immunotherapy, they may still be considered for inclusion in the extensive-stage cohort.\n\nExclusion Criteria:\n\nExclusion Criteria for Limited-Stage Small Cell Lung Cancer (LS-SCLC):\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC).\n2. No efficacy assessment record, or missing efficacy assessment data.\n3. Presence of other primary malignancies; history of allogeneic organ transplantation.\n4. Major surgery (excluding diagnostic biopsy) within 4 weeks prior to the first dose.\n5. History of substance abuse (e.g., drug addiction), long-term alcoholism, or AIDS or HIV carrier.\n6. Active autoimmune disease, or history of autoimmune disease with potential for relapse.\n7. Current systemic corticosteroid therapy (e.g., equivalent to \\>10 mg prednisone daily) or use of any other form of immunosuppressive therapy within 14 days prior to the first dose.\n8. Prior treatment with any antibody\u002Fdrug targeting T-cell co-regulatory proteins (immune checkpoints), including but not limited to PD-1, PD-L1, CTLA-4, TIM-3, and LAG-3.\n9. Interstitial lung disease (ILD) or history of ILD requiring corticosteroid therapy.\n10. History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), idiopathic pneumonia, or evidence of active pneumonitis on screening chest CT.\n11. Receipt of live vaccine within 28 days prior to the first dose of study drug.\n12. Any other disease or condition that contraindicates chemoradiotherapy, including but not limited to active infection, within 6 months post-myocardial infarction, symptomatic heart disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmias), and immunosuppressive therapy.\n13. Unresolved toxicity of Grade 2 or higher (according to CTCAE version 5.0).\n14. Pregnant or breastfeeding women; men or women of childbearing potential who are unwilling to use adequate contraceptive measures.\n15. Evidence of inherited bleeding diathesis or coagulation disorders.\n16. Prior history of malignancy (excluding skin cancer, or in situ breast cancer, oral cancer, or cervical cancer with life expectancy \\>3 years).\n\nExclusion Criteria for Extensive-Stage Small Cell Lung Cancer (ES-SCLC):\n\n1. Pulmonary carcinoid or non-small cell lung cancer, unless transformed SCLC is ruled out.\n2. No efficacy assessment record, or missing efficacy assessment data.\n3. History of severe anaphylactic\u002Fallergic reaction to humanized antibodies or fusion proteins.\n4. Acute exacerbation of chronic obstructive pulmonary disease (COPD) or other pulmonary diseases requiring hospitalization.\n5. Active or prior autoimmune disease (within the past 2 years) or history of primary immunodeficiency.\n6. Progression after immunotherapy; prior or concurrent diagnosis of any other malignancy, excluding non-melanoma skin cancer or carcinoma in situ of the cervix.\n7. Any other disease or condition that contraindicates chemoradiotherapy, including but not limited to active infection, within 6 months post-myocardial infarction, symptomatic heart disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmias), or immunosuppressive therapy.\n8. Unresolved toxicity of Grade 2 or higher (according to CTCAE version 5.0).\n9. Current or prior history of autoimmune disease or immunodeficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, and rheumatoid arthritis.\n10. History of idiopathic pulmonary fibrosis (IPF), organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonia; or evidence of active pneumonitis on chest CT scan. Patients with a history of radiation pneumonitis (fibrosis) within the radiation field may be enrolled.\n11. Pregnant or breastfeeding women; men or women of childbearing potential who are unwilling to use adequate contraceptive measures.",{"count":626,"type":23},500,"2 Years","By establishing a prospective clinical cohort for small cell lung cancer (SCLC) and systematically collecting high-quality real-world data integrating clinical, imaging, pathological, and molecular dimensions, this study aims to enable personalized treatment for distinct SCLC subtypes. Furthermore, by evaluating the influence of radiotherapy timing, dose and fractionation, and target selection on efficacy and toxicity, we aim to identify the optimal radio-immunotherapy combination regimen that maximizes the synergistic effect in SCLC patients.",[630,30,31,631],"Small Cell Lung Cancer ( SCLC )","Personalized Cancer Treatment",[633,30,31,631],"Small Cell Lung Cancer (SCLC)","2026-04-27",{"date":550,"type":40},{"date":637,"type":40},"2026-04-01",{"date":639,"type":23},"2030-03-31",{"name":641,"class":47},"Shanghai Chest Hospital",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":24,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":48},"100612562","virtual-vs-telephone-education-in-radiotherapy-100612562","NCT07255196","Virtual Vs Telephone Education in Radiotherapy","Virtual Vs Telephone Education in Radiotherapy - Randomized Clinical Trial","VIPER-RT","Inclusion Criteria:\n\n* 18 years or older\n* Access to an internet connected device with a microphone and camera\n* Able to communicate in English with\u002Fwithout a translator\n* Receiving radical breast cancer radiotherapy\n\nExclusion Criteria:\n\n* Previous radiotherapy treatment",{"count":651,"type":23},130,[459],"The goal of this clinical trial is to compare whether the use of videoconferencing in breast cancer patients undergoing radiotherapy is better for pre-treatment education than telephone calls. The main question it aims to answer is in breast cancer patient receiving radiotherapy, does videoconferencing, compared to telephone calls for pre-treatment education result in decreased procedural fears and concerns? The investigators hypothesize that the use of videoconferencing for pre-treatment radiotherapy education will decrease breast cancer patients' procedural fears and concerns. Researchers will compare the current standard of care in a 30 minute radiation therapist led pre-treatment education call to the intervention of a 45 minute radiation therapist led videoconferencing call to see if the intervention reduces patient procedural fears and concerns, anxiety levels, and has higher patient satisfaction. Participants will be asked to complete questionnaires at three time points: 1. Baseline - at time of study consent. 2. CT-Simulation - after their radiotherapy CT-Simulation appointment. 3. Day 1 Treatment - after their first day of radiotherapy treatment.",[655,30],"Patient Education",[657,658,655],"Virutal Care","Videoconferencing",{"date":611,"type":40},{"date":661,"type":40},"2025-12-20",{"date":663,"type":23},"2026-12",{"name":665,"class":47},"University Health Network, Toronto"]